NovaTears® / HYLO® Range
Dry Eye Disease
ApprovedCommercial - Growing Eye Care category
Key Facts
Indication
Dry Eye Disease
Phase
Approved
Status
Commercial - Growing Eye Care category
Company
About AFT Pharmaceuticals
AFT Pharmaceuticals is a publicly listed, integrated pharmaceutical company with a mission to develop and commercialize innovative products that address unmet health needs. Founded in 1997, it has achieved consistent revenue growth by leveraging a dual strategy of in-licensing/distribution and proprietary R&D, most notably with its world-first Maxigesic® combination analgesic platform. The company has successfully expanded from its New Zealand base to establish a significant presence in Australia, Asia, and Europe, demonstrating robust commercial execution and a focus on niche therapeutic areas like pain management, ophthalmology, and gastroenterology.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |